Placental growth factor is a potent vasodilator of rat and human resistance arteries
- 1 March 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 294 (3) , H1381-H1387
- https://doi.org/10.1152/ajpheart.00922.2007
Abstract
The objectives of this study were to determine whether placental growth factor (PlGF) exerts a vasodilatory effect on rat uterine vessels (arcuate arteries and veins) and to examine regional differences in reactivity by comparing these responses to those of comparably sized mesenteric vessels. We also sought to examine and compare its effects on human uterine and subcutaneous vessels. All vessels were studied in vitro, under pressurized (rat) or isometric wire-mounted (human) conditions, and exposed to a range of PlGF concentrations. Inhibitors of nitric oxide and prostaglandin synthesis were included in an effort to understand the causal mechanism(s). In rat uterine arteries, the effects of receptor inhibition and activation using selective ligands for VEGFR-1 (PlGF) vs. VEGFR-2 (VEGF-E) were determined, and real-time RT-PCR was performed to evaluate the effect of pregnancy on relative abundance of VEGFR-1 and VEGFR-2 message in the vascular wall. PlGF was a potent vasodilator of all vessels studied, with greatest sensitivity observed in rat uterine arteries. Pregnancy significantly augmented dilator sensitivity to PlGF, and this effect was associated with selective upregulation of VEGFR-1 message in the pregnant state. The contribution of nitric oxide was appreciable in rat and human uterine arteries, with lesser effects in rat uterine veins and mesenteric arteries, and with no observable effect in human subcutaneous vessels. Based on these results, we conclude that PlGF is a potent vasodilator of several vessel types in both humans and rats. Its potency and mechanism vary with physiological state and vessel location and are mediated solely by the VEGFR-1 receptor subtype. Gestational changes in the uterine circulation suggest that this factor may play a role in modulating uterine vascular remodeling and blood flow during the pregnant state.Keywords
This publication has 18 references indexed in Scilit:
- Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 ExpressionHypertension, 2007
- Angiogenic factors and preeclampsiaFrontiers in Bioscience-Landmark, 2007
- Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lungCritical Care Medicine, 2005
- Vascular Endothelial Growth Factor (VEGF)-A165-induced Prostacyclin Synthesis Requires the Activation of VEGF Receptor-1 and -2 HeterodimerPublished by Elsevier ,2005
- Mechanism of VEGF-Induced Uterine Venous HyperpermeabilityJournal of Vascular Research, 2005
- Uterine Venous Permeability in the Rat Is Altered in Response to Pregnancy, Vascular Endothelial Growth Factor, and Venous ConstrictionEndothelium, 2005
- Vascular Endothelial Growth Factor-Induced Nitric Oxide- and PGI2-Dependent Relaxation in Human Internal Mammary ArteriesJournal of Cardiovascular Pharmacology, 2004
- The mechanism of EDHF-mediated responses in subcutaneous small arteries from healthy pregnant womenAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Immediate and delayed VEGF‐mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathwaysBritish Journal of Pharmacology, 2002
- Transactivation of Vascular Endothelial Growth Factor (VEGF) Receptor Flk-1/KDR Is Involved in Sphingosine 1-Phosphate-stimulated Phosphorylation of Akt and Endothelial Nitric-oxide Synthase (eNOS)Journal of Biological Chemistry, 2002